Expression of heparan sulphate N-deacetylase/N-sulphotransferase by vascular smooth muscle cells

Histochemical Journal

Volumn 34, Issue 3-4, 2002, Pages 131-137

  Bingley, John A ^a   Hayward, Ian P ^a   Girjes, Adeeb A ^a   Campbell, Gordon R ^a   Humphries, Donald E ^b   Stow, Jennifer L ^a   Campbell, Julie H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; SULFOTRANSFERASE; AMIDASE; HEPARITIN SULFOTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BIOSYNTHESIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; FIBROBLAST; GOLGI COMPLEX; INTIMA; MACROPHAGE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RAT; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; CELL CULTURE; CORONARY BLOOD VESSEL; CYTOLOGY; ENZYMOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAST CELL; MOUSE; MOUSE MUTANT; SPRAGUE DAWLEY RAT; THORACIC AORTA;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

AMIDOHYDROLASES; AMINO ACID SEQUENCE; ANIMALS; AORTA, THORACIC; BLOTTING, WESTERN; CELLS, CULTURED; CORONARY VESSELS; HUMANS; IMMUNOHISTOCHEMISTRY; MAST CELLS; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; PHENOTYPE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SULFOTRANSFERASES;

EID: 0036523159     PISSN: 00182214     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020938430120     Document Type: Article

References (34)

1. Aikawa J, Esko J (1999) Molecular cloning and expression of a third member of the heparan sulfate/heparin GlcNac N-deacetylase/N-sulfotransferase family. J Biol Chem 274: 2690-2695.
2. Aikawa J, Grobe K, Tsujimoto M, Esko J (2001) Multiple isozymes of heparan sulfate/heparin GlcNAc N-deacetylase/GlcN N-sulfotransferase. J Biol Chem 276: 5876-5882.
3. Bingley JA, Hayward IP, Campbell GR, Campbell JH (2001) Relationship of glycosaminoglycan and matrix changes to vascular smooth muscle cell phenotype modulation in rabbit arteries following acute injury. J Vasc Surg 33: 155-164.
4. Bingley JA, Hayward IP, Campbell JH, Campbell GR (1998) Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J Vasc Surg 28: 308-318.
5. Campbell GR, Campbell JH (1987) Phenotypic modulation of smooth muscle cells in primary culture. In: Campbell JH, Campbell GR, eds. Vascular Smooth Muscle in Culture. Boca Raton: CRC Press, pp 39-56.
6. Campbell JH, Campbell GR (1993) Culture techniques and their applications to studies of vascular smooth muscle. Clin Sci 85: 510-513.
7. Campbell JH, Rennick RE, Kalevitch SG, Campbell GR (1992) Heparan sulphate-degrading enzymes induce modulation of smooth muscle phenotype. Exp Cell Res 200: 156-167.
8. Castellot JJ, Wright TC, Karnovsky MJ (1987) Regulation of vascular smooth muscle cell growth by heparin and heparan sulfate. Sem Thromb Haem 13: 489-503.
9. Clowes AW, Karnovsky MJ (1977) Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265: 625-626.
10. Dalferes ER, Radhakrishnamurthy B, Ruiz H, Berenson GS (1987) Composition of proteoglycans from human atherosclerotic lesions. Exp Molec Pathol 47: 363-376.
11. David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H (1992) Developmental changes in heparan sulfate expression: In situ detection with mAbs. J Cell Biol 119: 961-975.
12. Esko JD, Lindahl U (2001 ) Molecular diversity of heparan sulfate. J Clin Invest 108: 169-173.
13. Fan G, Xiao L, Cheng L, Wang X, Sun B, Gengxi H (2000) Targeted disruption of NDST-1 gene leads to pulmonary hypoplasia and neonatal respiratory distress in mice. FEBS Lett 467: 7-11.
14. Fritze LMS, Reilly CF, Rosenberg RD (1985) An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol 100: 1041-1049.
15. Girjes AA, Keriakous D, Hayward IP, Campbell GR, Campbell JH (2001) Cloning of genes differentially regulated during change in vascular smooth muscle phenotype. FEBS Lett 509: 341-342.
16. Hein M, Fischer J, Kim DK, Hein L, Pratt RE (1996) Vascular smooth muscle cell phenotype influences glycosaminoglycan composition and growth effects of extracellular matrix. J Vasc Res 33: 433-441.
17. Hollmann J, Schmidt A, von Bassewitz D-B, Buddecke E (1989) Relationship of sulfated glycosaminoglycans and cholesterol content in normal and atherosclerotic human aorta. Arteriosclerosis 9: 154-158.
18. Hoover RL, Rosenberg R, Haering W, Karnovsky MJ (1980) Inhibition of rat arterial smooth muscle cell proliferation by heparin II. In vitro studies. Circ Res 47: 578-583.
19. Humphries DE, Sullivan BM, Aleixo MD, Stow JL (1997) Localization of human heparan glycosaminyl N-deacetylase/N-sulphotransferase to the trans-Golgi network. Biochem J 325: 351-357.
20. Humphries DE, Wong GW, Friend DS, Gurish MF, Qiu W, Huang C, Sharpe AH, Stevens RL (1999) Heparin is essential for the storage of specific granule proteases in mast cells. Nature 400: 769-772.
21. Li Z-Y, Hirayoshi K, Suzuki Y (2000) Expression of N-deacetylase/sulfotransferase and 3-O-sulfotransferase in rat alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 279: L292-L301.
22. Lindahl U, Kusche M, Lidholt K, Oscarrson LG (1989) Biosynthesis of heparin and heparan sulfate. In: Lane DA, Lindahl U, eds. Heparin. London: Arnold, pp 548-574.
23. Manderson JA, Mosse PRL, Safstrom JA, Young SB, Campbell GR (1989) Balloon catheter injury to rabbit carotid artery. I. Changes in smooth muscle cell phenotype. Arteriosclerosis 9: 289-298.
24. Mosse PRL, Campbell GR, Wang ZL, Campbell JH (1985) Smooth muscle phenotypic expression in human carotid arteries. Lab Invest 53: 556-562.
25. Pikas DS, Eriksson I, Kjellén L (2000) Overexpression of different isoforms of glucosaminyl N-deacetylase/N-sulfotransferase results in distinct heparan sulfate N-sulfation patterns. Biochemistry 39: 4552-4558.
26. Radhakrishnamurthy B, Srinivasan SR, Eberle K, Ruiz H, Dalferes ER, Sharma C, Berenson GS (1988) Composition of proteoglycans synthesised by rabbit aortic smooth muscle cells explants in culture and effect of experimental atherosclerosis. Biochim Biophys Acta 964: 231-243.
27. Ringvall M, Ledin J, Holmborn K, van Kuppevelt T, Ellin F, Eriksson I, Olofsson AM, Kjellen L, Forsberg E (2000) Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N-sulfotransferase-1. J Biol Chem 275: 25926-25930.
28. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L (1997) Heparan sulfate proteoglycans of the cardiovascular system. J Clin Invest 99: 2062-2070.
29. Salmivirta M, Lidholt K, Lindahl U (1996) Heparan sulfate: A piece of information. FASEB J 10: 1270-1279.
30. Schmidt A, Buddecke E (1990) Bovine aortic smooth muscle cells synthesize two functionally different proteoheparan sulphate species. Exp Cell Res 189: 269-275.
31. Schmidt A, Lemming G, Yoshida K, Buddecke E (1992) Molecular organisation and antiproliferative domains of arterial tissue heparan sulfate. Eur J Cell Biol 59: 322-328.
32. Toma L, Berninsone P, Hirschberg CB (1998) The putative heparin-specific N-acetylglucosaminyl N-deacetylase/N-sulfotransferase also occurs in non-heparin-producing cells. J Biol Chem 273: 22458-22465.
33. Wight TN (1989) Cell Biology of Arterial Proteoglycans. Arteriosclerosis 9: 1-20.
34. Williams SP, Mason RM (1991) Modulation of proteoglycan synthesis by bovine vascular smooth muscle cell proliferation and treatment with heparin. Arch Biochem Biophys 287: 386-396.